B. Riley Securities Reiterates Buy on Journey Medical, Lowers Price Target to $13

Benzinga · 2d ago
B. Riley Securities analyst Mayank Mamtani reiterates Journey Medical (NASDAQ:DERM) with a Buy and lowers the price target from $15 to $13.